Salivary glands carcinomas, paranasal sinus cancers and melanoma of the head and neck: An update about rare but challenging tumors

Current Opinion in Oncology

Volumn 18, Issue 3, 2006, Pages 258-265

  Lalami, Yassine ^a   Vereecken, Pierre ^b   Dequanter, Didier ^a   Lothaire, Phillipe ^a   Awada, Ahmad ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Melanoma of the head and neck; Paranasal sinus cancer; Salivary gland carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IMIQUIMOD; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; THIOSULFATE; TRASTUZUMAB; TUMOR MARKER; VASCULOTROPIN; NEW DRUG;

ANOREXIA; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RESEARCH; CANCER SCREENING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DIARRHEA; DRUG DOSE REGIMEN; DRUG TARGETING; DYSPNEA; EDEMA; FATIGUE; HEAD AND NECK CANCER; HEADACHE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MELANOMA; MULTIMODALITY CANCER THERAPY; NAUSEA; PARANASAL SINUS CANCER; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; RARE DISEASE; REVIEW; SALIVARY GLAND CARCINOMA; SENTINEL LYMPH NODE BIOPSY; ADJUVANT THERAPY; BLINDNESS; CARCINOMA; DRUG DELIVERY SYSTEM; GENETICS; HEAD AND NECK TUMOR; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; MULTICENTER STUDY; PALLIATIVE THERAPY; PARANASAL SINUS TUMOR; PATHOLOGY; RADIOTHERAPY; SALIVARY GLAND TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLINDNESS; CARCINOMA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MELANOMA; MULTICENTER STUDIES AS TOPIC; NEOADJUVANT THERAPY; PALLIATIVE CARE; PARANASAL SINUS NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; SALIVARY GLAND NEOPLASMS; SENTINEL LYMPH NODE BIOPSY;

EID: 33646707803     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000219255.30220.90     Document Type: Review

References (85)

1. Kokemueller H, Brueggemann N, Swennen G, et al. Mucoepidermoid carcinoma of the salivary glands: clinical review of 42 cases. Oral Oncol 2005; 41:3-10.
2. Kokemueller H, Swennen G, Brueggemann N, et al. Epithelial malignancies of the salivary glands: clinical experience of a single institute: a review. Int J Oral Maxillofac Surg 2004; 33:423-432.
3. XXV Congress of the International Academy of Pathology: proceedings book. Newly recognised salivary gland tumours. Pathol Int 2004; 54:3245-3255.
4. Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th ed. UICC International Union Against Cancer; 2002.
5. Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch Head and Neck Oncology Cooperative Group. Head Neck 2004; 26:681-693.
6. Lima RA, Tavares MR, Dias FL, et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg 2005; 133:702-708. A comprehensive review of significant prognostic factors among the most frequent salivary glands cancers.
7. Kasamatsu A, Endo Y, Uzawa K, et al. Identification of candidates genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridisation and oligonucleotide microarray analyses. Int J Biochem Cell Biol 2005; 37:1869-1880. This is a presentation of the input of microarray technology in salivary glands carcinomas.
8. Kainuma K, Katsuno S, Hashimoto S, et al. Identification of differentially expressed genes in salivary gland tumors with cDNA microarray. Auris Nasus Larynx 2004; 31:261-268.
9. In der Maur CD, Klokman WJ, van Leeuwen FE, et al. Increased risk of breast cancer development after diagnosis of salivary gland tumour. Eur J Cane 2005; 41:1311-1315.
10. Van Valckenborgh I. Salivary and mammary gland tumorigenesis in PLAG1 transgenic mice. Doctoral thesis. KU Leuven, Belgium.
11. Bell RB, Dierks EJ, Homer L, et al. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005; 63:91 7-928.
12. Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 2004; 26:154-162.
13. Terhaard CHJ, Lubsen H, Coen RN, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005; 61:103-111. This is an updated review about radiotherapy for the management of salivary gland malignancies.
14. Airoldi M, Gabriele AM, Gabriele P, et al. Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma. Tumori 2001; 87:14-17.
15. Laurie SA, Su YB, Pfister DG. Chemotherapy in the management of metastatic adenoid cystic carcinoma: a systematic review [abstract]. Proc Am Soc Clin Oncol 2005; abstract 5581.
16. Airoldi M, Cortesina G, Giordano C, et al. Update and perspectives on non-surgical treatment of salivary gland malignancies. Acta Otorhinolaryngol Ital 2003; 23:368-376.
17. Agulnik M, Siu LL An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents. Curr Med Chem Anti-Cancer Agents 2004; 4:543-551. This is a comprehensive and complete review of medical management of salivary glands cancers.
18. Raguse JD, Gath HJ, Bier J, et al. Docetaxel (Taxotere) in recurrent high grade mucoepidermoid carcinoma of the major salivary glands. Oral Oncol 2004; 40:5-7.
19. An J, Sun JY, Yuan Q, et al. Proteomics analysis of differentially expressed metastatic-associated proteins in adenoid cystic carcinoma cell lines of human salivary gland. Oral Oncol 2004; 40:400-408.
20. Francioso F, Carinci F, Tosi L, et al. Identification of differentially expressed genes in human salivary gland tumors by DNA microarrays. Mol Cancer Ther 2002; 1:533-538.
21. Westernoff TH, Jordan RC, Regezi JA, et al. Beta-6 integrin, tenascin-C, and MMP-1 expression in salivary gland neoplasms. Oral Oncol 2005; 41:170-174.
22. Maruya S, Kies MS, Williams M, et al. Differential expression of p63 (Delta N and TA) isotypes in salivary gland neoplasms: biological and diagnostic implications. Hum Pathol 2005; 36:821-827.
23. Alves FA, Pires FR, de Almeida OP, et al. PCNA, Ki-67 and p53 expressions in submandibular salivary gland tumours. Int J Oral Maxillofac Surg 2004; 33:593-597.
24. Carlinfante G, Lazzaretti M, Ferrari S, et al. P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate: aclinico-pathologic study of 21 cases with long-term follow-up. Pathol Res Pract 2005; 200:791-799.
25. Kishi M, Nakamura M, Nishimine M, et al. Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas. Oral Oncol 2005; 41:161-169. A review about genetic modifications in the tumorogenesis of salivary glands cancers.
26. Lim JJ, Kang S, Lee MR, et al. Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med 2003; 32:552-561.
27. Glisson B, Colevas D, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cane Res 2004; 10:944-946.
28. Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005; 103:2526-2533.
29. Nguyen LH, Black MJ, Hier M, et al. Her2/neu and Ki67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands. J Otolaryngol 2003; 32:328-331.
30. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2003; 39:724-727.
31. Locati LD, Rinaldi G, Bossi P, et al. Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol 2005; 41:97-98.
32. Chen CHC, Liu BY, Wang JT, et al. Expression of epidermal growth factor in salivary adenoid cystic carcinoma. Proc Natl Sci Counc 2001; 25:90-96.
33. Glisson BS, Blumenschein G, Francisco M, et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer [abstract]. Proc Am Soc Clin Oncol 2005; abstract 5532.
34. Burris HA, Hurwitz H, Claire Dees E, et al. Phase I safety, and clinical activity study of Lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23:5305-5313.
35. Freier K, Flechtenmacher C, Walch A, et al. Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol 2005; 41:934-939.
36. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005; 23:585-590.
37. Alcedo JC, Fabrega JM, Arosemana JR, et al. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 2004; 26:829-831.
38. Faivre S, Raymond E, Casiraghi O, et al. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 2005; 23:6271-6273.
39. Bruce IA, Slevin NJ, Homer JJ, et al. Synergistic effects of imatinib (STI571) in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs 2005; 16:719-726.
40. Slevin NJ, Mais KL, Bruce I, et al. Imatinib with cisplatin in recurrent and/or metastatic adenoid cystic carcinoma: preliminary results of a phase II study of 18 patients with response assessed by morphological and functional imaging. Proc ECCO 2005; abstract 1015: 292-293.
41. Porceddu S, Martin J, Shanker G, et al. Paranasal sinus tumors: Peter Mac Callum Cancer Institute experience. Head Neck 2004; 26:322-330.
42. Blanch JL, Ruiz AM, Alos L, et al. Treatment of 125 sinonasal tumors: prognostic factors, outcome and follow-up. Otolaryngol Head Neck Surg 2004; 131:973-976.
43. Cantu G, Solero CL, Miceli R, et al. Which classification for ethmoid malignant tumors involving the anterior skull base? Head Neck 2005; 27:224-231.
44. El Mofty S, Lu D. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing (cylindric cell) carcinoma of the sinonasal tract: a distinct clinicopathological and molecular disease entity. Am J Surg Pathol 2005; 29:1367-1372.
45. Enepekides DJ. Sinonasal undifferentiated carcinoma: an update. Curr Opin Otolaryngol Head Neck Surg 2005; 13:222-225.
46. Orvidas LJ, Lewis JE, Weaver AL, et al. Adenocarcinoma of the nose and paranasal sinuses: a retrospective study of diagnosis, histologic characteristics and outcomes in 24 patients. Head Neck 2005; 27:370-375.
47. Yom SS, Rashid A, Rosenthal DI, et al. Genetic analysis of sinonasal adenocarcinoma phenotypes: distinct alterations of histogenetic significance. Mod Pathol 2005; 18:315-319.
48. Ariza M, Llorente JL, Alarez-Marcas C, et al. Comparative genomic hybridization in primary sinonasal adenocarcinomas. Cancer 2004; 100:335-341.
49. Helmbrecht S, Affolter A, Finger S, et al. Altered expression of cell cycle regulators p21, p27 and p53 in tumors of salivary glands and paranasal sinuses. Oncol Rep 2005; 13:1089-1094.
50. Bashir AA, Robinson RA, Benda JO, et al. Sinonasal adenocarcinoma: immunohistochemical marking and expression of oncoproteins. Head Neck 2003; 25:763-771.
51. Ganlyl I, Patel SG, Singh B, et al. Craniofacial resection for malignant paranasal sinus tumors: report of an international collaborative study. Head Neck 2005; 27:575-584. A comprehensive review about the role of surgery in paranasal sinus carcinomas.
52. Blanco AI, Clifford Chao KS, Ozyigit G, et al. Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59:51-58.
53. Pacholke HD, Amdur RJ, Luis DA, et al. The role of intensity modulated radiation therapy for favorable stage tumor of the nasal cavity or ethmoid sinus. Am J Clin Oncol 2005; 28:474-478. Presentation of a new irradiation technique for paranasal sinus malignancies.
54. Mock U, Georg D, Bogner J, et al. Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys 2004; 58:147-154.
55. Duthoy W, Boterberg T, Claus F, et al. Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer 2005; 104:71-82.
56. Rischin D, Porceddu S, Peters L, et al. Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck 2004; 26:435-441.
57. Homma A, Furuta Y, Suzuki T, et al. Superselective intra-arterial infusion of cisplatin and concurrent radiotherapy for advanced paranasal sinus cancer. Proc Am Soc Clin Oncol 2003; abstract 2085.
58. Samant S, Robbins KT, Vang M, et al. Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg 2004; 130:948-955.
59. Madison ML, Sorenson JM, Samant S, et al. The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation. J Neurooncol 2005; 72:67-75.
60. Licitra L, Locati LD, Cavina R, et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol 2003; 14:367-372.
61. INK4A and H-Ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Int J Cancer 2003; 105:196-203.
62. Licitra L, Suardi S, Bossi P, et al. Prediction of TP53 status for primary cisplatin, fluorouracil and leucovorin chemotherapy in ethmoid sinus intestinaltype adenocarcinoma. J Clin Oncol 2004; 22:4901-4906.
63. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
64. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma. II: Sun exposure. Eur J Cancer 2005; 41:45-60.
65. Cho E, Rosner BA, Colditz GA. Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev 2005; 14:1241-1244.
66. Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005; 97:195-199.
67. Purdue MP, From L, Kahn HJ, et al. Etiologic factors associated with p53 immunostaining in cutaneous malignant melanoma. Int J Cancer 2005; 117:486-493.
68. Neale RE, Forman D, Murphy MF, et al. Site-specific occurrence of non-melanoma skin cancers in patients with cutaneous melanoma. Br J Cancer 2005; 93:597-601.
69. Yu CH, Chen HH, Liu CM, et al. HMB-45 may be a more sensitive marker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas. J Oral Pathol Med 2005; 34:540-545.
70. Gillgren P, Brattstrom G, Frisell J, et al. Effect of primary site on prognosis in patients with cutaneous malignant melanoma: a study using a new model to analyse anatomical locations. Melanoma Res 2005; 15:125-132.
71. Staibano S, Pepe S, Lo Muzio L, et al. Poly(adenosine diphosphate-ribose A) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005; 36:724-731.
72. Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br J Dermatol 2005; 152:673-678.
73. Kalina P, Bevilacqua P. Perineural extension of facial melanoma. Neuroradiology 2005; 47:372-374.
74. Lin D, Kashani-Sabet M, McCalmont T, et al. Neurotropic melanoma invading the inferior alveolar nerve. J Am Acad Dermatol 2005; 53 (Suppl 1):s120-s122.
75. Daryanani D, Plukker JT, de Jong MA, et al. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res 2005; 15:119-124.
76. MacNeill KN, Ghazarian D, McCready D, et al. Sentinel lymph node biopsy for cutaneous melanoma of the head and neck. Ann Surg Oncol 2005; 12:726-732.
77. Lin D, Kashani-Sabet, Singer MI. Role of the head and neck surgeon in sentinel lymph node biopsy for cutaneous head and neck melanoma. Laryngoscope 2005; 115:213-217.
78. Grunhagen DJ, Eggermont AM, van Geel AN, et al. Prognostic factors after cervical lymph node dissection for cutaneous melanoma metastases. Melanoma Res 2005; 15:179-184.
79. Maccauro M, Villano C, Aliberti G, et al. Lymphoscintigraphy with intraoperative gamma probe sentinel node dissection: clinical impact in patients with head and neck melanomas. Q J Nucl Med Mol Imaging 2005; 49:245-251.
80. Arora A, Lowe L, Su L, et al. Wide excision without radiation for desmoplastic melanoma. Cancer 2005; 104:1462-1467.
81. Ballo MT, Bonnen MD, Garden AS, et al. Adjuvant irradiation for cervical lymph node metastases for melanoma. Cancer 2003; 97:1789-1796.
82. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 2005; 103:313-319.
83. Martin JM, Porceddu S, Weih L, et al. Outcomes in sinonasal mucosal melanoma. Aust N Z J Surg 2004; 74:838-842.
84. Stevenson O, Ahmed I. Lentigo maligna: prognosis and treatment options. Am J Clin Dermatol 2005; 6:151-164.
85. Ray CM, Kluk M, Grin CM, et al. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 2005; 44:428-434.